Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Ginkgo Biloba | Sabroxy (Oroxylum indicum) | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses | — |
| Timing | With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest. | — |
| Cycle Duration | Ongoing; no cycling required. Clinical trials typically run 22-26 weeks. | — |
| Evidence Level | strong_human | Emerging |
Standardized extract (EGb 761) contains flavonoid glycosides (24%) and terpene lactones (6% — ginkgolides A/B/C and bilobalide) that act through multiple pathways: potent free radical scavenging and inhibition of membrane lipid peroxidation; antagonism of platelet-activating factor (PAF) via ginkgolides; enhancement of cerebral blood flow through nitric oxide-mediated vasodilation and reduced blood viscosity; and increased prefrontal dopamine and acetylcholine release via acylated flavonol glycosides. Bilobalide provides direct neuroprotection against excitotoxicity and mitochondrial dysfunction.
120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses
With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest.
Ongoing; no cycling required. Clinical trials typically run 22-26 weeks.
Contains oroxylin A — a flavonoid that inhibits PDE (phosphodiesterase), increases BDNF, and modulates dopamine signaling. Enhances focus and motivation without stimulant side effects. Also acts as a mild MAO-B inhibitor, preserving dopamine levels.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →